News

Ophthalmology Times2h
Palatin releases updated results from responder analyses of phase 3 Melody-1 trial in dry eye
Responder analysis was conducted to evaluate the percentage of patients achieving complete symptom resolution across 13 pre-specified symptom endpoints.
The Manila Times on MSN4h
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness ...
Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025
Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today outlined a framework for a ...
Immutep Quarterly Activities Report Q3 FY25
Media Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestonePivotal TACTI-004 trial design presented at the European Lung Cancer Congress (ELCC) 2 ...
Applied Clinical Trials Online2h
Johnson & Johnson's TAR-200 for Bladder Cancer Shows High Rates of Disease-Free Survival, Bladder Preservation
Early findings from Johnson & Johnson’s Phase IIb SunRISe-1 trial show the promise of TAR-200 in patients with Bacillus ...
Unexpected hives reaction seen in trial of mRNA vax against HIV
A safety analysis of mRNA vaccination in a phase 1, randomized, open-label clinical trial evaluated the safety and ...
The Manila Times6h
Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
Verona Pharma will host a live webcast and a conference call at 9:00 a.m. EDT / 2:00 p.m. BST on Tuesday, April 29, 2025, to discuss the first quarter 2025 financial results and corporate update. To ...
Patient outcomes may improve with tailored treatment guided by tissue plus liquid biopsies vs. individually
Patients with advanced solid tumors experienced significantly improved survival outcomes when receiving a tailored therapy ...
Positive Long-Term Outlook for Narrow-Moat Medpace Despite Macroeconomic Pressure in Near Term
Medpace has historically maintained a conservative balance sheet. At year-end 2024, cash and cash equivalents totaled $669 million. Medpace generated nearly $191 million in cash flow from operating ...
Verona Pharma plc: Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses exc ...
iTeos Therapeutics Inc.: iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H&N-202 and TIG-006 HNSCC with ~200 patients anticipated in 2025 - Cash ...
Australian Associated Press7h
KOLON TISSUEGENE HIGHLIGHTS LONG-TERM SAFETY DATA AND POTENTIAL U.S. FDA PATHWAY FOR TG-C AT OARSI WORLD CONGRESS
In the spirit of reconciliation, Australian Associated Press acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our ...